Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Can a prior rhinovirus infection protect against COVID-19?

Researchers at the Yale School of Medicine found that rhinovirus accelerates interferon-stimulated genes.

21 Jun 2021

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

In a recent study, a group of researchers aimed to identify exactly how early SARS-CoV-2 was circulating throughout the United States.

21 Jun 2021

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice. The compound reduces the risk of severe coronavirus disease 2019 (COVID-19) by inhibiting viral replication in the lower respiratory tract. The study is currently available on the bioRxiv* preprint server.

18 Jun 2021

Study examines SARS-CoV-2 replication in cells using super-resolution microscopy

Despite tremendous efforts by the global scientific community to curb the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by developing more efficient testing protocols, therapies, and vaccines at a rapid pace, relatively little is known about the dynamics of SARS-CoV-2 replication within cells.

18 Jun 2021

Nanodecoys made from human lung spheroid cells can neutralize SARS-CoV-2

Nanodecoys made from human lung spheroid cells (LSCs) can bind to and neutralize SARS-CoV-2, promoting viral clearance and reducing lung injury in a macaque model of COVID-19.

18 Jun 2021

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Researchers reporting on findings from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial in the UK are recommending that any therapeutic use of REGEN-COV may be best restricted to individuals without detectable antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Jun 2021

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

17 Jun 2021

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.

17 Jun 2021

How the common cold can provide protection against COVID-19

In a recent study, researchers found that prior infection with the rhinovirus can provide a more effective immune response against SARS-CoV-2 infection.

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Long-term exposure to poor air quality increases COVID-19 risk, research finds

Even as governments across the United States consider lifting mask mandates and relaxing preventative measures as vaccination numbers creep up, new research from a UCLA-led team has found that such basic techniques significantly reduce the risk of getting COVID-19.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

A new bioRxiv* preprint demonstrates how a combination of antibodies to two different regions on the viral spike could enhance neutralization efficiency as well as prevent the emergence of resistant variants.

15 Jun 2021

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

A new study, released as a preprint on the bioRxiv* server, describes the biological effects induced by mutations in two circulating VOCs. These are the alpha and beta strains, also called B.1.1.7 and B.1.351, respectively.

15 Jun 2021

Alkaloids show potential as treatments for COVID-19

To further study these organic compounds, researchers from Kermanshah University of Medical Sciences, Iran, and Universidad de Santiago de Chile, Chile, reviewed the role of alkaloids as a potential antiviral, specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They presented the chemistry, plant sources, and antiviral effects of alkaloids and their anti-SARS-CoV-2 effect.

15 Jun 2021

Immune memory responses differ between SARS-CoV-2 and influenza A

Researchers in Canada have shown that the long-lasting immunity that develops following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by different T cell responses than those observed for influenza A virus-specific immune memory.

14 Jun 2021

Plant-based diet appears to offer protection against hypertension and preeclampsia

A plant-based diet appears to afford significant protection to rats bred to become hypertensive on a high-salt diet, scientists report. When the rats become pregnant, the whole grain diet also protects the mothers and their offspring from deadly preeclampsia.

14 Jun 2021

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

A new study, released as a preprint on the bioRxiv* server, presents a new monoclonal antibody (MAb) called DZIF-10c that powerfully neutralizes SARS-CoV-2, including the current variants of concern (VOCs). With high bioavailability in the lungs and wide distribution in the body, the antibody was able to prevent SARS-CoV-2 infection in mice after intranasal administration.

14 Jun 2021

Fatty acid binding site on SARS-CoV-2 spike triggers spike monomer crosstalk that is key to infectivity

A new study, released as a preprint on the bioRxiv* server, examines the role played by a fatty acid called linoleic acid (LA) that attaches at a binding site near the receptor-binding domain (RBD) of the spike protein. The spike exists as a homotrimer in open or closed conformations. In the former, at least one RBD points upwards.

14 Jun 2021

Forkhead box O's potential therapeutic use in the treatment of COVID-19

In a recent study, Indian researchers from the Department of Biochemistry, University of Delhi, reviewed a possible vital coalition of FoxOs - the Forkhead Box O subfamily of protein transcription factors, with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the etiological agent of COVID-19 (coronavirus disease).

13 Jun 2021

Angiotensin News and Research

Further Reading

Can a prior rhinovirus infection protect against COVID-19?

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

Study examines SARS-CoV-2 replication in cells using super-resolution microscopy

Nanodecoys made from human lung spheroid cells can neutralize SARS-CoV-2

Regeneron mAb cocktail benefits hospitalized patients with no natural SARS-CoV-2 antibody response

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

How the common cold can provide protection against COVID-19

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Long-term exposure to poor air quality increases COVID-19 risk, research finds

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

Alkaloids show potential as treatments for COVID-19

Immune memory responses differ between SARS-CoV-2 and influenza A

Plant-based diet appears to offer protection against hypertension and preeclampsia

Intranasal monoclonal SARS-CoV-2 antibody therapy shows promise in preclinical trials

Fatty acid binding site on SARS-CoV-2 spike triggers spike monomer crosstalk that is key to infectivity

Forkhead box O's potential therapeutic use in the treatment of COVID-19

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News